To keep sales force busy, Lilly takes on new drug
Eli Lilly and Co. has bought the rights to co-market a new cholesterol-fighting drug in the U.S., giving it a third heart drug for sales personnel
to push.
Health Care & Life Sciences
Articles
Lilly scurries to get out from under Zyprexa cloud
Another year of rapid change at Eli Lilly and Co. did little to move the company out from under the cloud cast by its best-selling
drug, Zyprexa.
Health care industry braces for reform
Congress is on the cusp of transforming health insurance—if it can pass a health reform bill that was losing popularity
late in the year.
First decade of century marked by buyouts and bubbles
The decade witnessed a massive terrorist attack, two wars, and a building-and-buyout boom fueled by easy credit.
Conseco raises nearly $223 million in stock offering
The Carmel-based life and health insurer immediately applied $161 million of the funds to its bank loans.
Investors cheer Senate bill while WellPoint cries foul
Exemption for not-for-profit health plans could saddle WellPoint with nearly $2 billion a year in new taxes.
Lilly pays $90 million for autoimmune drug
By acquiring an experimental medicine for rheumatoid arthritis, the Indianapolis-based drugmaker is increasing its focus on autoimmune
diseases.
Health Care bill clears key Senate test
Landmark health care legislation backed by President Barack Obama passed its sternest Senate test in the pre-dawn hours early
Monday, overcoming Republican delaying tactics on a 60-40 vote that all but assures its passage by Christmas.
Building trades leaders flock to Wishard meetings
Hundreds of potential contractors turned out for informational meetings this week about construction work on a new Wishard Memorial Hospital.
Hoosier biz groups oppose Senate health bill
Group presidents tell Indiana senators that the reform bill would expand dysfunctions of current health care systems.
Setbacks in diabetes market batter Roche
Roche Diagnostics Corp., once the darling of the U.S. diabetes-device market, is now licking its wounds. And
it’s mulling whether to keep fighting on all fronts or to pull back.
Judge fines woman waging Web war against plastic surgeon
Judge Sarah Evans Barker declared a Massachusetts woman in contempt of court for failing to remove her negative Internet
postings about an Indianapolis cosmetic surgeon.
First Indiana Future Fund off to a slow start
More than half of the venture capital fund’s original investors took a pass on its $58 million successor, the newly launched
INext.
Senate rejects drug-importation proposal
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers
such as Indianapolis-based Eli Lilly and Co. a victory.
$60M Lilly Endowment grant to fund IU physician research
Indiana University, which has received nearly $600 million from the endowment over the last three decades, will leverage the
new gift to increase its
scientific discoveries and commercialize life science innovations.
Lilly wins approval for long-acting Zyprexa
Once-a-month injection of best-selling drug will have patents that could extend until 2018.
Dormir acquires two sleep companies
Carmel firm using $12 million in venture capital for buying spree is now nation’s second-largest operator of sleep centers.
Lilly charity gives $1M to new IU health school
The Eli Lilly and Co. Foundation has given Indiana University $1 million to start a school of public health at Indiana University-Purdue
University Indianapolis.
Noble of Indiana to provide in-home services to disabled
The service will launch in February. Its goal is to serve 15 clients by June 30, 2010.
Health care reform would push state to hike Medicaid pay to docs
An actuarial report prepared by the local office of Milliman Inc., a Seattle-based consulting firm, projects
that the state of Indiana would have to hike its Medicaid payments by one-third in order to entice more
doctors into the program.